Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase

Eric Yuk Fai Wan; Boyuan Wang; Sukriti Mathur; Cheyenne I Ying Chan; Vincent Ka Chun Yan; Francisco Tsz Tsun Lai; Celine Sze Ling Chui; Xue Li; Carlos King Ho Wong; Philip Hei Li; Chak Sing Lau; Ian Chi Kei Wong; Esther Wai Yin Chan

doi:10.1016/j.jinf.2023.02.029

Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase

J Infect. 2023 Jun;86(6):622-625. doi: 10.1016/j.jinf.2023.02.029. Epub 2023 Feb 22.

Affiliations

¹ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
² Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
³ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
⁴ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China.
⁵ Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China; School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
⁶ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China; Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
⁷ Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
⁸ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China; Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Aston Pharmacy School, Aston University, Birmingham B4 7ET, UK. Electronic address: wongick@hku.hk.
⁹ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, Hong Kong, China; Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China. Electronic address: ewchan@hku.hk.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents / therapeutic use
COVID-19 Drug Treatment
COVID-19*
Humans
Ritonavir* / therapeutic use

Substances

molnupiravir
nirmatrelvir
Ritonavir
Antiviral Agents